Twist Bioscience Corp vs Union Pacific Corporation — how do they compare? Twist Bioscience Corp trades at $162.88 (market cap $10.08B), while Union Pacific Corporation trades at $277.87 (market cap $165.27B). The key difference: Union Pacific Corporation is far larger — about 16.4× Twist Bioscience Corp's market cap, and Union Pacific Corporation pays a 2.04% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Union Pacific Corporation for 105 Days on average.
| TWST | UNP | |
|---|---|---|
Market Cap | $10.08B | $165.27B |
Volume | 4,229,037 | 1,474,117 |
Sector | Health | Industrials |
52-Week High | $205.00 | $310.62 |
52-Week Low | $25.45 | $216.37 |
Typical Hold Time | 27 Days | 105 Days |
Enterprise Value | $10.01B | $194.33B |
Dividend Yield | — | 2.04% |
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Union Pacific (UNP) trades at $277.51, up 1.03% with a bullish technical signal and strong fundamental performance. The stock shows robust profitability with 28.85% net margins and 39.7% ROE, supported by consecutive earnings beats in Q1 and Q2 2026. Recent developments include the deployment of battery-electric locomotives and progress on the Norfolk Southern combination, while analyst consensus remains strongly positive with a $332.10 price target.
UNP presents a compelling investment case with strong operational execution and pricing power, though merger uncertainty and fuel cost pressures pose near-term risks. The stock's current valuation at 22.53 P/E offers reasonable upside to analyst targets, supported by consistent dividend payments and infrastructure advantages in the irreplaceable freight rail network.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →